Clinical trial
Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in…
NCT00382980 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00382980 |
|---|---|
| Title | Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults |
| Official title | A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Trial of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Immunization With Inactivated, Vero Cell-Culture Derived Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Young Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological, Drug |
| Interventions | Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo |
| Enrollment | 308 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Oct 2, 2006 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: